Observational studyBMJ (Clinical research ed.)2020
Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study.
Observational study in BMJ (Clinical research ed.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Reducing re-excision rates in breast conserving surgery with Margin Probe: systematic review.The British journal of surgery · 2024Pooled it
- Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study.BMJ (Clinical research ed.) · 2023Pooled it
- Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients.Annals of surgical oncology · 2022Pooled it
- Low-Fat Dietary Modification and Risk of Ductal CarcinomaCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Trial
- A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast.JNCI cancer spectrum · 2021Trial
- Breast Cancer Outcomes From Ductal Carcinoma In Situ: A Population-Based Cohort Study.International journal of cancer · 2026Article
- Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study.Breast cancer research and treatment · 2026Article
- Economic evaluation of artificial intelligence for cancer detection in the UK breast screening programme.British journal of cancer · 2026Article
- High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities.Nature communications · 2026Article
- Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic status.International journal of cancer · 2026Article
- Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy.Current oncology (Toronto, Ont.) · 2026Article
- Surgical margins in breast conserving surgery for ductal carcinoma in situ of the breast and clinical outcomes: a national audit with long term follow-up.EClinicalMedicine · 2025Article
- SEPT9 methylation as a diagnostic and predictive biomarker in the progression of ductal carcinoma in situ to invasive breast cancer.Scientific reports · 2025Article
- Healthy lifestyles, screening, and breast cancer mortality in women with different risk of disease.The oncologist · 2025Article
- Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Circulating tumor cells as predictive biomarkers in the risk stratification of DCIS: Evidence of early dissemination.Science advances · 2025Article
- Estimated health outcomes of breast cancer screening in the national breast and cervical cancer early detection program by race/ethnicity.Cancer causes & control : CCC · 2025Article
- Single-Cell Expression Analysis of Ductal Carcinoma In Situ Identifies Complex Genotypic-Phenotypic Relationships Altering Epithelial Composition.Cancer research · 2025Article
- Incidence trends of ductal carcinoma in situ in New Zealand women between 1999 and 2022.Breast cancer research and treatment · 2025Article
- Risk perception of patients with ductal carcinomaHistology and histopathology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the long term risks of invasive breast cancer and death from breast cancer after ductal carcinoma in situ (DCIS) diagnosed through breast screening.
designPopulation based observational cohort study.
settingData from the NHS Breast Screening Programme and the National Cancer Registration and Analysis Service.
participantsAll 35 024 women in England diagnosed as having DCIS by the NHS Breast Screening Programme from its start in 1988 until March 2014.
main outcome measuresIncident invasive breast cancer and death from breast cancer.
resultsBy December 2014, 13 606 women had been followed for up to five years, 10 998 for five to nine years, 6861 for 10-14 years, 2620 for 15-19 years, and 939 for at least 20 years. Among these women, 2076 developed invasive breast cancer, corresponding to an incidence rate of 8.82 (95% confidence interval 8.45 to 9.21) per 1000 women per year and more than double that expected from national cancer incidence rates (ratio of observed rate to expected rate 2.52, 95% confidence interval 2.41 to 2.63). The increase started in the second year after diagnosis of DCIS and continued until the end of follow-up. In the same group of women, 310 died from breast cancer, corresponding to a death rate of 1.26 (1.13 to 1.41) per 1000 women per year and 70% higher than that expected from national breast cancer mortality rates (observed:expected ratio 1.70, 1.52 to 1.90). During the first five years after diagnosis of DCIS, the breast cancer death rate was similar to that expected from national mortality rates (observed:expected ratio 0.87, 0.69 to 1.10), but it then increased, with values of 1.98 (1.65 to 2.37), 2.99 (2.41 to 3.70), and 2.77 (2.01 to 3.80) in years five to nine, 10-14, and 15 or more after DCIS diagnosis. Among 29 044 women with unilateral DCIS undergoing surgery, those who had more intensive treatment (mastectomy, radiotherapy for women who had breast conserving surgery, and endocrine treatment in oestrogen receptor positive disease) and those with larger final surgical margins had lower rates of invasive breast cancer.
conclusionsTo date, women with DCIS detected by screening have, on average, experienced higher long term risks of invasive breast cancer and death from breast cancer than women in the general population during a period of at least two decades after their diagnosis. More intensive treatment and larger final surgical margins were associated with lower risks of invasive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.